Auspherix Appoints New Clinician to Scientific Advisory Board
News Jul 04, 2016
William’s career to date has focused on research in antimicrobial pharmacokinetics and pharmacodynamics, mathematic modelling of antimicrobial agents and individualisation of antimicrobial therapy. He is an NIHR Clinical Scientist and Professor of Therapeutics and Infectious Diseases at The University of Liverpool, UK and was recently appointed as Chair in the Department of Molecular and Clinical Pharmacology at The University of Liverpool. A Fellow of the Royal Australasian College of Physicians and the Royal College Pathologists of Australasia. He was previously Chair in Therapeutics and Infectious Diseases at The University of Manchester. He has a PhD in antimicrobial pharmacology from The University of Manchester. Alongside his advisory role to Auspherix, William is also Scientific Advisor to the ESCMID Fungal Infection Study Group, Secretary to the EUCAST Antifungal Susceptibility Testing Sub-Committee and was recently appointed to the ICAAC Program Committee for Antimicrobial Pharmacokinetics, Pharmacodynamics and General Pharmacology.
Founded in 2013, Auspherix is developing a new class of anti-bacterials with a unique profile suggestive of a novel mechanism of action.
Dr Neil Miller, CSO of Auspherix, said: “With his hands on clinical experience, and a depth of knowledge gained during his careers in the anti-infectives space, William’s input and guidance will make an invaluable addition to the insight and steer we get from our SAB as we progress our novel anti-bacterial drug candidates through pre-clinical development towards our first-in-human clinical trial.”
The Auspherix’s SAB is chaired by Professor Ian Charles, co-founder and previously CSO of the Company, and now Director of the Institute of Food Research/Quadram Institute. He has a strong focus on translational research and infectious diseases, and was previously co-founder and CSO of Arrow Therapeutics. As well as new member Professor William Hope, other SAB members are: Auspherix CSO Neil Miller; Auspherix Board member Dr Jared Silverman, VP of Research at VL32 and who contributed to the discovery of three novel antibiotics during his career within Cubist Pharmaceuticals; Dr Alan Naylor, an independent consultant and medicinal chemist with over 30 years of R&D experience within GlaxoSmithKline; and Professor David Livermore, Professor of Medical Microbiology at the University of East Anglia and serves on the UK Government’s Antimicrobial Resistance & Healthcare Associated Infection Advisory Committee.
Neural Computer Hears Like HumansNews
Modelling the human senses is an incredibly complex task. Our brains arrange cells into complex hierarchies that process information from our surroundings. Now, a group at MIT have created a model of the human auditory cortex that can hear sounds and music in the same way that humans do.READ MORE
Stable Beta-Amyloid Dimers Identified in Alzheimer’s BrainsNews
A recent study exploited state-of-the-art mass spectrometry to provide the first direct evidence of beta-amyloid dimers in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers. Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.
Protein Target Identified That Could Prevent StrokesNews
Scientists have identified a protein, called GPR68, that senses blood flow and tells small blood vessels called arterioles when to dilate. The researchers believe medications that activate GPR68 could one day be useful to treat medical conditions, including ischemic stroke.READ MORE